Last updated on January 2018

Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure


Brief description of study

Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure

Detailed Study Description

The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) = 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).

Clinical Study Identifier: TX149514

Contact Investigators or Research Sites near you

Start Over

Mirza Muratovic

University of South Florida-Morsani College of Medicine
Tampa, FL USA
  Connect »